Cartesian Therapeutics (RNAC) Non Operating Income (2024 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Non Operating Income of -$12.7 million for Q1 2026, down 403.49% year-over-year from $4.2 million in Q1 2025, and up 45.17% quarter-over-quarter from -$23.1 million in Q4 2025.
Cartesian Therapeutics (RNAC) Non Operating Income (2024 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Non Operating Income for 3 consecutive years, with -$12.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income fell 403.49% year-over-year to -$12.7 million; the TTM figure through Mar 2026 stood at -$13.0 million (down 189.85% YoY), while the FY2025 annual figure was $3.9 million, up 111.76% from the prior year.
- Non Operating Income rose to -$12.7 million in Q1 2026 per RNAC's latest filing, from -$23.1 million in the prior quarter.
- Across five years, Non Operating Income topped out at $37.7 million in Q2 2025 and bottomed at -$43.5 million in Q1 2024.
- Historically, Non Operating Income has averaged -$4.7 million across 3 years, with a median of -$6.6 million in 2024.
- Annual changes were most pronounced in 2025 — Non Operating Income jumped 47617.72% — and 2026, when it tumbled 403.49%.
- Cartesian Therapeutics' Non Operating Income stood at $16.8 million in 2024, then slumped by 237.97% to -$23.1 million in 2025, then soared by 45.17% to -$12.7 million in 2026.
- Business Quant data shows RNAC's Non Operating Income at -$12.7 million in Q1 2026, -$23.1 million in Q4 2025, and -$14.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | 44.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.92 Mn |
| Mar 31, 2026 | -12.68 Mn |
| Dec 31, 2025 | -23.13 Mn |
| Sep 30, 2025 | -14.84 Mn |
| Jun 30, 2025 | 37.70 Mn |
| Mar 31, 2025 | 4.18 Mn |
| Dec 31, 2024 | 16.77 Mn |
| Sep 30, 2024 | -6.61 Mn |
| Jun 30, 2024 | 79,000.00 |
| Mar 31, 2024 | -43.48 Mn |